Fibroblast growth factor receptor 2 fusions as a target for treating cholangiocarcinoma

Curr Opin Gastroenterol. 2015 May;31(3):264-8. doi: 10.1097/MOG.0000000000000171.

Abstract

Purpose of review: This review will cover the role of the fibroblast growth factor pathway in the pathogenesis, targeted therapy potential and prognostic value in patients with cholangiocarcinoma (CCA).

Recent findings: Recent studies that have identified fibroblast growth factor receptor 2 (FGFR2) fusions, prognostic implications of FGFR2 fusions, treatment strategies that target FGFR2 in CCA and future directions for understanding and targeting the FGFR2 pathway in this disease, will be discussed.

Summary: Understanding the role of the FGFR2 pathway as a disease pathogenetic mechanism and the ability to develop targeted therapies and diagnostics surrounding this concept are critical elements toward developing novel targeted approaches in CCA.

Trial registration: ClinicalTrials.gov NCT02150967 NCT02265341.

Publication types

  • Review

MeSH terms

  • Bile Duct Neoplasms / drug therapy
  • Bile Duct Neoplasms / genetics
  • Bile Duct Neoplasms / pathology*
  • Bile Ducts, Intrahepatic / pathology*
  • Biomarkers, Tumor / genetics
  • Cell Line, Tumor
  • Cholangiocarcinoma / drug therapy
  • Cholangiocarcinoma / genetics
  • Cholangiocarcinoma / pathology*
  • ErbB Receptors / metabolism*
  • Humans
  • Molecular Sequence Data
  • Molecular Targeted Therapy*
  • Prognosis
  • Receptor, Fibroblast Growth Factor, Type 2 / metabolism*
  • Translocation, Genetic
  • Treatment Outcome

Substances

  • Biomarkers, Tumor
  • EGFR protein, human
  • ErbB Receptors
  • FGFR2 protein, human
  • Receptor, Fibroblast Growth Factor, Type 2

Associated data

  • ClinicalTrials.gov/NCT02150967
  • ClinicalTrials.gov/NCT02265341